

# **Safety of laparoscopic ChOlecystectomy performed by Trainee surgeons with different CHolangiographic techniques (SCOTCH)**

## ***Contents***

1. Study Summary
2. Key study contact
3. Glossary of terms
4. Background
5. Patients and study design
  - 5.1 Study design
  - 5.2 Rationale for Study Design
    - 5.2 Study group
    - 5.3 Potential Benefit to Patients
    - 5.4 Patient risks
6. Study Objectives
  - 6.1 Primary Outcomes
    - 6.2 Secondary outcomes
    - 6.3 Evaluated parameters
  7. Selection of Subjects
    - 7.1 Consent
    - 7.2 Inclusion Criteria
    - 7.3 Exclusion Criteria
    - 7.4 Selection of participants
  8. Study procedures
  9. Statistical analysis
    - 9.1 Sample size
    - 9.2 Expected duration of the trial
  10. Strength and limitations
  10. Direct access to Source Data and documents
  11. Ethics & Regulatory Approvals
  12. Quality Assurance
    - 12.1 Data Handling
    - 12.2 Data Management
13. Publication Policy
14. Financial Aspects
15. References
16. Appendixes
  - 16.1 APPENDIX A Questionnaire on anatomical identification of the bile ducts
  - 16.2 APPENDIX B NASA task load
  - 16.3 APPENDIX C Visual analog scale for surgeon's satisfaction
  - 16.4 APPENDIX D Adverse event score
  - 16.5 APPENDIX E Classification for bile duct injuries (ATOM, Stasberg, LAU)

## 1. Study summary

Study Title	<b>Safety of laparoscopic ChOlecystectomy performed by Trainee surgeons with different CHolangiographic techniques (SCOTCH)</b>
Internal ref. no. (or short title)	<b>SCOTCH study</b>
Study Design	Multicenter prospective interventional trial
Study Participants	Patients
Endpoints	<b>Primary endpoints</b> Time to reach CVS with the utilisation of three different intraoperative imaging modality during LC performed by ST
Summary of eligibility criteria	<p><b>Inclusion Criteria</b></p> <ul style="list-style-type: none"> <li>- Patient scheduled for elective laparoscopic cholecystectomy</li> <li>- Patient age <math>\geq</math> 18 years</li> <li>- Patient able to give consent to the procedure</li> </ul> <p><b>Exclusion Criteria</b></p> <ul style="list-style-type: none"> <li>- Open cholecystectomy</li> <li>- Emergency laparoscopic cholecystectomy</li> <li>- Allergy towards iodine, lohexol or indocyanine green</li> <li>- Liver or renal insufficiency</li> <li>- Thyrotoxicosis</li> <li>- Pregnancy or lactation</li> <li>- Legally incompetent for any reason</li> <li>- Withdrawal of inclusion consent at any time</li> <li>- Age outside inclusion range</li> </ul>
Arms of the study	<p><b>Group CVS-WL (control group):</b> the CVS is achieved in white light, without the utilization of an intraoperative imaging technique. CVS in white light was selected as the control group since it constitutes the actual recognized standard in clinical practice.</p> <p><b>Group IOC:</b> the CVS is achieved with the help of intraoperative cholangiography</p> <p><b>Group NIR-C:</b> the CVS is achieved with the help of near-infrared fluorescence cholangiography</p>
Version and date of protocol amendments	Vers. n.1.1- 15/11/2020
Clinicaltrials.gov Registration number	NCT04863482

## 2. Key Study Contacts

Chief Investigator	Prof Mario Guerrieri Address: Clinica chirurgica generale e d'urgenza, Università Politecnica delle Marche, Via Conca 71, Ancona, Italy Telephone: 071 596 3084 Email: m.guerrieri@staff.univpm.it
Study Co-ordinator	Dr Monica Ortenzi Address: Clinica chirurgica generale e d'urgenza, Università Politecnica delle Marche, Via Conca 71, Ancona, Italy Telephone: 392 4770853 Email: m.ortenzi@staff.univpm.it
Key Protocol Contributors	Prof Mario Guerrieri Dr Monica Ortenzi

## 3. Glossary of Terms

**LC**= laparoscopic cholecystectomy

**ST**= surgical trainee

**CVS**= critical view of Strasberg

**IOC**= intraoperative cholangiography

**NIR-C**= Near-infrared fluorescence cholangiography

**CBD**= common bile duct

**BDI**= bile duct injury

#### 4. Background

Laparoscopic cholecystectomy (LC) gained popularity among general surgeons in 1990s and rapidly become one of the most commonly performed procedures in digestive surgery [1, 2], with more than one million cholecystectomies being performed in the United States per year [3]. LC remains also one of the most commonly performed procedure by general surgeons during the training period [4, 5].

Even if previous report LC cases performed by surgical trainees (ST) are not associated with higher operative morbidity [6], the length of operative time is significantly increased when compared with that of LC cases performed by attending surgeons, due, most of all, to difficulties in identifying the anatomical structures [7, 8], and this sometimes leads to an attending surgeon taking away the case from the trainee.

Furthermore, despite the fact that LC has proven to be a safe procedure, the rate of common bile duct (BDI) injury still remains unacceptably high even in the hands of minimally invasive trained surgeons [9] ranging from 0.2 to 1.5% in individual reports [10, 11-14], much higher than initial reports [14, 15], associated with significant morbidity and mortality, lower quality of life and increased costs, related to additional health care measures, loss of work days, and insurance claims [2,10, 16, 17]. Way et al reported that, in 97 % of cases, non-technical errors, predominantly relating to perceptual errors, in which the operator was led to make false assumptions regarding the position of the bile duct in relation to the anatomy at hand, were at the root cause of the injury. [18] From these observation many of the existing recommendations to avoid BDI insist on the importance of the establishment of the critical view and understanding the relevant anatomy, aided by adequate retraction and visualization. [19]

The correct identification of Calot's triangle, sometimes hard even in expert hand, may be particularly challenging for ST leading at those misidentification of the structures that are the most frequent causes of BDI during LC as previously stated. As a matter of fact, the most frequent site of CBD injury is below the bifurcation of the right and left hepatic ducts (65 %), and once anatomic confusion has led the surgeon astray, injury tends to occur in relatively predictable locations along the biliary tree [4]

With laparoscopic surgery, there is also loss of haptic input and stereoscopic depth perception, which predisposes to the misperception that leads to BDI [20] Various methods have been described to help the identification of the structures in Calot's triangle; these include intraoperative cholangiogram (IOC) [22], critical view of safety (CVS) [23] and the near-infrared fluorescent cholangiography (NIRF-C) [24].

Each of these technique have been proved to be useful and, at the same time, to have some intrinsic drawback that could be amplified when in unexperted hands.

The use of IOC during LC is well established [25] with the aim to detect of bile duct stones, defining biliary tree anatomy and the early recognition of iatrogenic common bile duct (CBD) injuries. [26-29]

Although regarded as a safe procedure with a low risk of complications, the merits of routine IOC usage remain an area of debate. Some studies suggest that it adds significant operating time and cost, without reducing the risk of detection of retained CBD stones or bile duct injury. [30-33] Others

demonstrated that the routine use of IOC for cholecystectomy plays a crucial role in the detection of intraoperative CBD stones and CBD injury.

It could be argued, however, that to perform IOC it is necessary to incise what is presumed to be the CD, which in itself may be the cause of a lateral injury of the CBD (or CHD) in case of mistaken anatomy [30] and, in a training setting, IOC can be difficult to teach and residents do not gain enough experience with it as not all surgeons perform it routinely and that [1]

The CVS, more than a technology the others, is a technique, introduced by Strasberg and Brunt in 1995, [23] and it is considered the gold standard to perform a safe cholecystectomy with identification of biliary structures (eg, cystic duct, common hepatic duct, and common bile duct) during dissection. Three criteria are required to achieve the CVS: (1) the hepatocystic triangle must be cleared of adipose and fibrotic tissues; the common bile duct and common hepatic duct must not be exposed; (2) the lower third of the gallbladder must be separated from the liver bed to expose the cystic plate; and (3) 2 and only 2 structures should be seen entering the gallbladder. In this case, the main drawback for ST is the necessity to dissect around the Calot's triangle to demonstrate the CVS. It can become challenging for an attending surgeon to supervise the resident to dissect and demonstrate CVS without any visual landmarks.

The most recently introduced intraoperative imaging technique is the near-infrared fluorescent cholangiography (NIRF-C), described by Ishizawa et al in 2009. [24] The NIRF-C allows a real-time enhanced visualization of the extrahepatic biliary tree by fluorescence. NIRF-C is based on the administration of a fluorophore, the indocyanine green, which is excreted in the biliary system, and on the use of a nearinfrared light source, exciting the fluorophore and enabling the visualization. NIRF-C offers some clear advantages when compared with the conventional cholangiography (real-time visualization of biliary tree, reduced costs, easy learning curve, lack of X-ray exposure, safer dissection of Calot's triangle, and possibility to associate fluorescent angiography to highlight vessels). [34, 35] Additionally, NIRF-C has shown a good potential as a teaching tool for trainees. [1, 36]

Previous report demonstrated the feasibility and safety of NIRFC [37]. Prospective study comparing IOC and NIRFC, that the latter is associated with a shorter duration of operation [38] and confirmed its non-inferiority to IOC to X-ray cholangiography in visualizing the critical junction during LC. [39]

Unfortunately, however, as confirmed the EURO-FIGS registry on fluorescence-guided surgery, there is a wide disparity in terms of protocols for NIRFC, across several European surgical centers, particularly in terms of ICG dose and timing of administration. [40]

The aim of this study is to address which of the techniques now available could be addressed as the best option in a training setting to enhance the learning curve, to ideally build a safe cholecystectomy training program and virtually eliminate the risk of BDI due to anatomic misinterpretation during the training period.

## **5. Patients and study design**

### **5.1 Study design**

The study will be a multicentre prospective observational study. Members of the Italian Society of Endoscopic Surgery [SICE] will be invited to participate. All participating centers will be required to register the study according to local regulations. Evidence of successful registration should be sent to your national network committee prior to beginning of data collection.

### **5.2 Study groups**

The enrolled patients will be divided into three groups, 1 control group and 2 treatment groups, according to the selected technique to achieve the CVS during LC:

**Group CVS-WL (control group):** the CVS is achieved in white light, without the utilization of an intraoperative imaging technique. CVS in white light was selected as the control group since it constitutes the actual recognized standard in clinical practice.

**Group IOC:** the CVS is achieved with the help of intraoperative cholangiography

**Group NIR-C:** the CVS is achieved with the help of near-infrared fluorescence cholangiography

### **5.3 Rationale for Study Design**

Since to date there is no consensus on which is the best technique to correctly identify the anatomy of the Calot's triangle during LC performed by ST, this trial would aim to propose a standard technique to be used in this peculiar setting.

### **5.4 Potential Benefit for Patients**

In teaching hospitals and, more generally in a training setting, overcoming the problem of providing high surgical quality while educating ST can be challenging. This may change in the future if residents are able to better identify the anatomy with IOIFC, shortening the learning curve and improving the safety profile of LC, that, in a clinical point of view, would translate into a shorter operative times and reduction of the potential risk of BDI.

### **5.5 Patient Risk**

There are no additional risks on the participation of this study as no additional procedures are being performed to clinical guidance. In accordance with standard care, patients shall receive written information regarding the index procedure.

## **6. Study objectives**

### **6.1 Primary Outcomes**

The primary objective is to compare NIFC, IOC and CVS-WL for identification of the junction between the cystic duct, the common hepatic duct and the CBD during LC performed by general surgery trainee always supported by an expert surgeon. The technique will be considered successful when the CVS will be achieved. The time to achieve the CVS will be recorded by an independent surgeon who will be present in the operative room during the procedure.

The definition of trainee will be on the number of the procedures performed before the beginning of the study. Surgeons who performed less than 30 procedures before the beginning of the study, since learning curve studies have determined the steep portion to consist of 10 to 30 operations [40–43]. The operating surgeon will complete a structured questionnaire focusing on anatomical identification of the bile ducts immediately after each operation (**Appendix A**) and a more generic

questionnaire on task load. (**Appendix B**) The surgeon's satisfaction score will be given on a subjective visual analogue scale ranging from 1 to 5 (1 = not satisfied, 5 = extremely satisfied). (**Appendix C**)

## 6.2 Secondary Outcomes

Secondary endpoints will be the ability to visualize the common hepatic duct (from the junction to the bifurcation), common bile duct (from the junction to the retroduodenal part) and the cystic duct (from the junction to the infundibulum of the gallbladder).

Other secondary outcomes will be short-term outcomes, procedural characteristics (operating time, intraoperative complications, need for conversion), rate and type of BDI, postoperative care characteristics (type of postoperative admission, length of postoperative stay, intensive care unit stay).

Intraoperative, unpredicted events will be recorded and classified according to a grade of unfavourable intraprocedural events. (**Appendix D**)

Short-term will be defined as within 30 days after surgery or until discharge, if the patient remained in hospital at that time. The size of the excised lesions and patients characteristics were assessed and compared as well.

## 6.3 Evaluated parameters

- i) Age
- ii) Sex
- iii) ASA scores
- iv) Preoperative work up
- v) Type of procedure (CVS-WL, NIFC, IOC)
- vi) Operative parameters (operative time, intraoperative complications)
- vii) BDI (according to the ATOM, Stasberg's and LAU classification [44-46] **Appendix E**)
- viii) How the BDI was diagnosed intraoperatively
- ix) Duration of cholangiography
- x) Time needed to obtain a CVS
- xi) Post-operative outcomes (post-operative complications, late complications, need of readmission, length of hospital stay)
- xii) Surgeons' ease at performing the procedure (questionnaire on identification of anatomical structures, NASA task load test)
- xiii) Surgeons' satisfaction (visual analog scale)

## 7. Selection of Subjects

Consecutive eligible patients will be recruited at the outpatient clinic in the participating center by the involved physician (surgeon). All patients fulfilling the above-mentioned criteria will be informed about the study by the physician. After consent is given, central data acquisition will take place web-based and patients will be treated according to the study protocol.

### 7.1 Consent

Potential participants will be counselled by a member of the research team directly involved with the study and who hold good clinical practice certification. Patients will be provided with written information and the consent form at the time of counselling with an opportunity to ask any questions. All patients participating in the study must hold capacity- this is an inclusion criteria and the absence of it an exclusion criteria.

## **7.2 Inclusion criteria**

- Patient scheduled for elective laparoscopic cholecystectomy
- Patient age  $\geq$  18 years
- Patient able to give consent to the procedure

## **7.3 Exclusion criteria:**

- Open cholecystectomy
- Emergency laparoscopic cholecystectomy
- Allergy towards iodine or indocyanine green
- Liver or renal insufficiency
- Thyrotoxicosis
- Pregnancy or lactation
- Legally incompetent for any reason
- Withdrawal of inclusion consent at any time
- Age outside inclusion range

## **8. Study procedures**

### **Critical view of Safety(CVS)**

The CVS has 3 requirements. First, the triangle of Calot must be cleared of fat and fibrous tissue. It does not require that the common bile duct be exposed. The second requirement is that the lowest part of the gallbladder be separated from the cystic plate, the flat fibrous surface to which the non peritonealized side of the gallbladder is attached. The cystic plate, which is sometimes referred to as the liver bed of the gallbladder, is part of the plate/sheath system of the liver. The third requirement is that 2 structures, and only 2, should be seen entering the gallbladder. Once these 3 criteria have been fulfilled, CVS has been attained). The rationale of CVS is based on a 2-step method for ductal identification that was and continues to be used in open cholecystectomy. First, by dissection in the triangle of Calot, the cystic duct and artery are putatively identified and looped with ligatures. Next, the gallbladder is completely dissected off the cystic plate, demonstrating that the 2 structures are the only structures still attached to the gallbladder. Time consumption and includes the period from the initial dissection and the obtaining of an acceptable view according to the previously described criteria in order to safely transect the cystic duct.

### **Intraoperative cholangiography (IOC)**

IOC is performed after dissection of the cystic duct in a standardised manner, by cannulation of the cystic duct with a catheter using either a Kumar or Olsen grasper. Leakage is controlled by injecting saline prior to injection of iodine contrast means, according to the centre usual habits. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardised manner. Time consumption includes

the period from application of the Kumar/Olsen grasper until it is removed again after obtaining a satisfactory cholangiogram and the cystic duct is transected.

### **Near infrared cholangiography (NIR-C)**

NIFC is performed injecting intravenously, 2.5-7.5 mg of indocyanine green (0.2 mg/kg) at the admission of the patients into the hospital, in patients admitted the same day of surgery, and at least 45 mins before the acquisition of the images. Indocyanine green rapidly binds to plasma proteins and is exclusively and entirely excreted by the hepatic parenchymal cells into the bile, starting within a few minutes after injection. During dissection, the fluorescence imaging mode is used when needed until critical view of safety is obtained. Before division of any tubular structure, the fluorescence imaging mode is routinely used again, and fluorescent angiography is performed by re-injecting the same dose of indocyanine green as initially used. After division of the cystic duct and artery, the fluorescence imaging mode is applied again to check for bile leakage. Time consumption includes the period from the initial dissection and the obtaining of an acceptable CVS and transect the cystic duct.

## **9. Statistical analysis**

Descriptive statistics will be provided for all discrete variables in the form of rates and proportions with 95% confidence intervals. Continuous variables will be described by mean, standard deviation, median and range. Overall survival, disease free survival, local recurrence rate and metastasis rate will be estimated using the method of Kaplan Meier. Exploratory comparisons of discrete variables will be performed using a Chi-squared test, using continuity correction or Fisher's exact test. Continuous variables will be compared using a Student's t-test, or a non-parametric equivalent (Wilcoxon). All tests will be two sided with a p-value of less than 0.05 considered to indicate statistical significance. Data will be analysed according to intention-to treat principles.

### **9.1 Sample size**

Sample size was estimated using simulations for a superiority design. Assuming a success rate of 80% for the conventional intraoperative cholangiography, 90 % for the intraoperative fluorescent cholangiography and . This was done for a range of sample sizes. We then analysed each dataset to test whether intraoperative fluorescent cholangiography was no more than 10% inferior to conventional intraoperative cholangiography in a one-sided test applying a 5% level of significance. In conclusion, 60 patients in each group would yield a power of 90%.

Prior to data collection, assuming a baseline structure detection rate of 20%, 300 subjects per group was the estimated sample size needed to detect a 10% absolute increase (from 20 to 30%) in extrahepatic biliary structure visualization rates, with 95% confidence and 80% power. In addition to comparing structure detection rates between the 2 study arms, exploratory analysis was performed to identify potential effect modifiers like age, sex, body mass index (BMI), liver

Based on power calculations to demonstrate superiority of NBI over WLE for the endoscopic diagnosis of coeliac disease, 328 patients would be required in total (44 in each group): calculated using a significance level (alpha) 5%, power 1 (beta) 95%, %success in control (WLE) group 60% [25] and % success in experimental group (NBI) 91% [24].

The sample size has been considered with reference to (1) recruitment (2) adequately powered calculations to be conducted to address the outcomes including inter-observer variation.

### **9.3 Expected Duration of Trial**

The trial is expected to run for 6 months (time from first patient recruitment to last patient evaluation). Data analysis will take a maximum of 3 months after this time.

### **11. Ethics & Regulatory Approvals**

The trial will be conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of GCP and in accordance with all applicable regulatory requirements including but not limited to the Research Governance Framework and the Medicines for Human Use (Clinical Trial) Regulations 2004, as amended in 2006 and any subsequent amendments.

This study protocol will be submitted for local REC review in addition with patient information leaflet and consent form. The protocol/ any amendments will follow the local REC process. The chief investigator shall provide annual REC reports as required and will notify the REC at the end of the study.

If the study is ended prematurely, the Chief Investigator will notify the REC, including the reasons for the premature termination.

### **12. Data Handling**

The Chief Investigator will act as custodian for the trial data. The following guidelines will be strictly adhered to:

All study data will be:

- Stored in line with the Medicines for Human Use (Clinical Trials) Amended Regulations 2006 and the Data Protection Act.
- archived in line with the Medicines for Human Use (Clinical Trials) Amended Regulations 2006 as defined in the Joint Clinical Trials Office Archiving SOP

### **13. Publication Policy**

It is intended that the results of the study will be reported and disseminated at international conferences and in peer-reviewed scientific journals. Two investigators for each of the involved centres will be included in the authors' list.

### **14. Financial Aspects**

The study does not require additional funding as all patients are not undergoing clinical procedures outside of their usual care. No other procedure is being performed that will require additionally funding than that to perform clinical investigation alone or histopathological analysis.

### **15. References**

1. ROY, Mayank, et al. Fluorescent incisionless cholangiography as a teaching tool for identification of Calot's triangle. *Surgical endoscopy*, 2017, 31.6: 2483-2490.
2. Pucher PH, Brunt LM, Davies N, Linsk A, Munshi A, Rodriguez HA, Fingerhut A, Fanelli RD, Asbun H, Aggarwal R, SAGES Safe Cholecystectomy Task Force (2018) Outcome trends and safety measures after 30 years of laparoscopic cholecystectomy: a systematic review and pooled data analysis. *Surg Endosc* 32(5):2175–2183. <https://doi.org/10.1007/s00464-017-5974-2>

3. National Center for Health Statistics. Health, United States, 2009. In Brief—medical technology (2010). [https://www.cdc.gov/nchs/data/abus/abus09 InBrief\\_MedicalTechnology.pdf](https://www.cdc.gov/nchs/data/abus/abus09 InBrief_MedicalTechnology.pdf). Accessed 4 Jan 2019
4. Richards MK, McAteer JP, Drake FT, Goldin AB et al (2015) A national review of the frequency of minimally invasive surgery among general surgery residents: assessment of ACGME case logs during 2 decades of general surgery resident training. *JAMA Surg* 150(2):169–172
5. Parsa CJ, Organ CH Jr, Barkan H (2000) Changing patterns of resident operative experience from 1990 to 1997. *Arch Surg* 135(5):570–573 discussion 3–5
6. Balaa F, Moloo H, Poulin EC et al (2007) Broad-based fellowships: a cornerstone of minimally invasive surgery education and dissemination. *Surg Innov* 14(3):205–210
7. Koulas SG, Tsimoyiannis J, Koutsourelakis I et al (2006) Laparoscopic cholecystectomy performed by surgical trainees. *JSLs* 10(4):484–487
8. Linn JG, Hungness ES, Clark S et al (2011) General surgery training without laparoscopic surgery fellows: the impact on residents and patients. *Surgery* 150(4):752–758
9. Velanovich V, Morton JM, McDonald M et al (2006) Analysis of the SAGES outcomes initiative cholecystectomy registry. *Surg Endosc* 20(1):43–50
10. Flum DR, Dellinger EP, Cheadle A, Chan L, Koepsell T (2003) Intraoperative cholangiography and risk of common bile duct injury during cholecystectomy. *JAMA* 289(13):1639–1644 in Denmark: outcome and risk factors for 20,307 patients from the national database. *Surg Endosc* 25(5):1630–1641. <https://doi.org/10.1007/s00464-010-1453-8>
11. Navez B, Ungureanu F, Michiels M, Claeys D, Muysoms F, Hubert C, Vanderveken M, Detry O, Detroz B, Closset J, Devos B, Kint M, Navez J, Zech F, Gigot JF, Belgian Group for Endoscopic Surgery (BGES) and the Hepatobiliary and Pancreatic Section (HBPS) of the Royal Belgian Society of Surgery (2012) Surgical management of acute cholecystitis: results of a 2-year prospective multicenter survey in Belgium. *Surg Endosc* 26(9):2436–2445
12. Törnqvist B, Strömberg C, Akre O, Enochsson L, Nilsson M (2015) Selective intraoperative cholangiography and risk of bile duct injury during cholecystectomy. *Br J Surg* 102(8):952–958. <https://doi.org/10.1002/bjs.9832>
13. Törnqvist B, Strömberg C, Persson G, Nilsson M (2012) Effect of intended intraoperative cholangiography and early detection of bile duct injury on survival after cholecystectomy: population based cohort study. *BMJ* 345:e6457. <https://doi.org/10.1136/bmj.e6457>
14. Waage A, Nilsson M (2006) Iatrogenic bile duct injury: a population-based study of 152 776 cholecystectomies in the Swedish inpatient registry. *Arch Surg* 141(12):1207–1213
15. Dolan JP, Diggs BS, Sheppard BC, Hunter JG (2005) Ten-year trend in the national volume of bile duct injuries requiring operative repair. *Surg Endosc* 19(7):967–973
16. Gartland RM, Bloom JP, Fong ZV, DeRoo C, Dwyer K, Quinn G, Lillemoe K, Mort E (2018) What have we learned from malpractice claims involving the surgical management of benign biliary disease?: A 128 million dollar question. *Ann Surg*. <https://doi.org/10.1097/sla.0000000000000315>
17. Fletcher DR, Hobbs MS, Tan P, Valinsky LJ, Hockey RL, Pikora TJ, Knuihan MW, Sheiner HJ, Edis A (1999) Complications of cholecystectomy: risks of the laparoscopic approach and protective effects of operative cholangiography: a population-based study. *Ann Surg* 229(4):449–457
18. Way LW, Stewart L, Gantert W, Liu K, Lee CM, Whang K, Hunter JG (2003) Causes and prevention of laparoscopic bile duct injuries: analysis of 252 cases from a human factors and cognitive psychology perspective. *Ann Surg* 237:460–469

19. Pucher PH, Brunt LM, Fanelli RD, Asbun HJ, Aggarwal R. SAGES expert Delphi consensus: critical factors for safe surgical practice in laparoscopic cholecystectomy. *Surg Endosc.* 2015 Nov;29(11):3074-85. doi: 10.1007/s00464-015-4079-z. Epub 2015 Feb 11. PMID: 25669635.
20. Cherrick GR, Stein SW, Leevy CM, Davidson CS (1960) IOC: observations on its physical properties, plasma decay, and hepatic extraction. *J Clin Invest* 39:592–600
21. Blom EM, Verdaasdonk EG, Stassen LP et al (2007) Analysis of verbal communication during teaching in the operating room and the potentials for surgical training. *Surg Endosc* 21(9):1560–1566
22. Mirizzi PL (1950) Operative cholangiography. *Revista espanola de las enfermedades del aparato digestivo y de la nutricion* 9(3):306–308
23. Strasberg SM, Hertl M, Soper NJ (1995) An analysis of the problem of biliary injury during laparoscopic cholecystectomy. *J Am Coll Surg* 180(1):101–125
24. Ishizawa T, Bandai Y, Kokudo N. Fluorescent cholangiography using indocyanine green for laparoscopic cholecystectomy: an initial experience. *Arch Surg.* 2009;144: 381-382
25. Photi ES, et al. The routine use of cholangiography for laparoscopic cholecystectomy in the modern era. *JSLs: Journal of the Society of Laparoendoscopic Surgeons*, 2017, 21.3.
26. Ludwig K, Bernhardt J, Steffen H, Lorenz D. Contribution of intra-operative cholangiography to incidence and outcome of common bile duct injuries during laparoscopic cholecystectomy. *Surg Endosc.* 2002;16:1098–1104.
27. Flum DR, Koepsell T, Heagerty P, Sinanan M, Dellinger P. Common bile duct injury during laparoscopic cholecystectomy and the use of intra-operative cholangiography. *Arch Surg.* 2001; 136:1287–1292.
28. Polat FR, Abci I, Coskun I, Uranues S. The importance of intra-operative cholangiography during laparoscopic cholecystectomy. *JSLs.* 2000;4:103–107.
29. Lill S, Rantala A, Pekkala E, et al. Elective laparoscopic cholecystectomy without routine intra-operative cholangiography: a retrospective analysis of 1101 consecutive cases. *Scand J Surg.* 2010;99:197–200.
30. Ding GQ, Cai W, Qin MF. Intra-operative cholangiography necessary during laparoscopic cholecystectomy for cholelithiasis? *World J Gastroenterol.* 2015;21:2147–2151.
31. Takada T, Strasberg SM, Solomkin JS, et al, Committee Tokyo Guidelines Revision (2013) TG13: Updated Tokyo Guidelines for the management of acute cholangitis and cholecystitis. *J Hepatobiliary Pancreat Sci* 20(1):1–7.
32. Sajid MS, Leaver C, Haider Z, Worthington T, Karanjia N, Singh KK. Routine on-table cholangiography during cholecystectomy: a systematic review. *Ann R Coll Surg Engl.* 2012;94: 375–380.
33. Soper NJ, Dunnegan DL. Routine versus selective intra-operative cholangiography during laparoscopic cholecystectomy. *World J Surg.* 1992;16:1133–1140.
34. Pesce A, Latteri S, Barchitta M, et al. Near-infrared fluorescent cholangiography—real-time visualization of the biliary tree during elective laparoscopic cholecystectomy [published online December 29, 2017]. *HPB (Oxford)*. doi:10.1016/j.hpb.2017.11.013.
35. Pesce A, Piccolo G, La Greca G, Puleo S. Utility of fluorescent cholangiography during laparoscopic cholecystectomy: a systematic review. *World J Gastroenterol.* 2015;21:7877-7883.
36. Agnus V, et al. Fluorescence-based cholangiography: preliminary results from the IHU-IRCAD-EAES EURO-FIGS registry. *Surgical Endoscopy*, 2019, 1-9.
37. Liu Yu, et al. A meta-analysis of indocyanine green fluorescence imaging-guided laparoscopic cholecystectomy for benign gallbladder disease. *Photodiagnosis and Photodynamic Therapy*, 2020, 101948.
38. Quaresima S, et al. Routine near infra-red indocyanine green fluorescent cholangiography versus intraoperative cholangiography during laparoscopic cholecystectomy: a case-matched comparison. *Surgical Endoscopy*, 2019, 1-9.
39. LEHRSKOV, L. L., et al. Fluorescence or X-ray cholangiography in elective laparoscopic cholecystectomy: a randomized clinical trial. *British Journal of Surgery*, 2020, 107.6: 655-661.
40. Sariego J, Spitzer L, Matsumoto T. The “learning curve” in the performance of laparoscopic cholecystectomy. *Int Surg* 1993;78:1–3.
41. Hawasli A, Lloyd LR. Laparoscopic cholecystectomy. The learning curve: report of 50 patients. *Am Surg* 1991;57:542–5.
42. Moore MJ, Bennett CL. The learning curve for laparoscopic cholecystectomy. *Am J Surg* 1995;170:55–9.

43. Cagir B, Rangraj M, Maffuci L, Herz BL. The learning curve for laparoscopic cholecystectomy. *J Laparoendosc Surg* 1994;4:419–27.
44. Fingerhut A, Dziri C, Garden OJ, Gouma D, Millat B, Neugebauer E, Paganini A, Targarona E (2013) ATOM, the all-inclusive, nominal EAES classification of bile duct injuries during cholecystectomy. *Surg Endosc* 27(12):4608–4619
45. Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. *J Am Coll Surg* 1995;180:101-125.
46. Lau WY, Lai EC. Classification of iatrogenic bile duct injury. *Hepatobiliary Pancreat Dis Int* 007;6:459-463.

## 16. Appendixes

### 16.1 APPENDIX A Questionnaire on anatomical identification of the bile ducts

#### Critical view of safety- WL (CVS)

1. What is the quality of visualization?

(Very poor) 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 (Excellent)

2. Has the CVS been achieved?

- Yes
- Probably
- Inconclusive

3. Would you transect the cystic duct based on this image?

- Yes
- No

#### Intraoperative cholangiography (IOC)

1. What is the quality of the IOC (grade best image)?

(Very poor) 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 (Excellent)

2. Is the duct that is cannulated the cystic duct?

- Yes
- Probably
- Inconclusive

3. Would you transect the cystic duct based on this image?

- Yes
- No

#### Near infrared cholangiography (NIFC)

1. What is the quality of the NIFC (grade best image)?

(Very poor) 1 – 2 – 3 – 4 – 5 – 6 – 7 – 8 – 9 – 10 (Excellent)

2. Was the junction well visible?

- Yes
- Probably
- Inconclusive


3. Would you transect the cystic duct based on this image?

- Yes
- No

*Adapted from Buddingh KT, et al. Documenting correct assessment of biliary anatomy during laparoscopic cholecystectomy. Surgical endoscopy, 2012, 26.1: 79-85.*

### 16.2 APPENDIX B NASA task load index





## 16.4 APPENDIX D Adverse events score

**Table 1** The intraoperative adverse event classification

Grade	Intraoperative adverse event classification	Percentage of adverse events identified from laparoscopic TME case video review pilot (%)	Examples in laparoscopic colorectal surgery
1	Minor error, no damage or corrective action required	60.1	Peritoneal tear; tissue avulsion from excess traction
2	Minor consequential error requiring corrective action but no change in post-operative care	37.1	Bleeding requiring a corrective step (swab/diathermy), wrong plane dissection—identified and corrected, serosal injury
3	Consequential error requiring major corrective action and/or change in post-operative pathway	2.4	Splenic capsule tear; re-do anastomosis; enterotomy, unplanned stoma
4	Life-threatening complication that requires major or immediate corrective action which led to a significant alteration of the post-operative pathway which may include re-operation or intensive care admission	0.1	Visceral injury; major haemorrhage; any complication necessitating ITU admission
5	Major consequential error resulting in death	0	Major vessel injury, air embolus

The five categories cover all observed intraoperative events by basing the grouping of the therapeutic consequences of the event. Illustrative examples for each category are shown. The vast majority of observed adverse events were seen to be grades I and II with fewer serious events identified

*Francis NK, Curtis NJ, Conti JA, Foster JD, Bonjer HJ, Hanna GB; EAES committees. EAES classification of intraoperative adverse events in laparoscopic surgery. Surg Endosc. 2018 Sep;32(9):3822-3829*

## 16.5 APPENDIX E

**Table 2** EAES classification matrix for bile duct injuries

Anatomic level	Anatomical characteristics					Vasculobiliary injury (yes=VBI+) and name of injured vessel (RHA, LHA, CHA, PV, MV); (no = VBI-)	Time of detection			Mechanism	
	Type and extent of injury						Ei (de visu, bile leak, IOC)	Ep	L	Me	ED
	occlusion		division								
	C	P*	C	P*	LS**						
MBD											
1											
2											
3											
4											
5											
6											
NMBD											


For each injury, the surgeon fills in the following matrix: (1) single injury (yes/no); (2) multiple injuries (yes/no). Then one matrix is filled in for each injury, as appropriate. For example, an injury made by an energy-driven (ultrasonic) dissector involving the superior biliary confluence with interruption of the right and left hepatic ducts, detected (intraoperatively) during the operation by the presence of bile would be classed as MBD 4 C VBI Ei, ED. The Connor Garden E6 injury is in fact a type 4 with LS: MBD 4 LS

EAES European Association for Endoscopic Surgery, MBD main biliary duct, NMBD nonmain biliary duct (Luschka duct, aberrant duct, accessory duct), level 1 ≥ 2 cm from lower border of superior biliary confluent, level 2 < 2 cm from lower border of superior biliary confluent, level 3 involves the superior biliary confluent but communication right left is preserved, level 4 involves superior biliary confluent but communication right left is interrupted, level 5a right or left hepatic duct, level 5b right sectorial duct but bile duct still in continuity, C complete, P partial, LS loss of substance, Me mechanical, ED energy driven, VBI vasculobiliary involvement, RHA right hepatic artery, LHA left hepatic artery, CHA common hepatic artery, PV portal vein, MV marginal vessels, Ei early intraoperative, Ep early postoperative, L late, OC intraoperative cholangiogram

<sup>a</sup> Indicate percentage of circumference, if known

<sup>b</sup> Indicate length, if known

Fingerhut A, Dziri C, Garden OJ, et al . ATOM, the all-inclusive, nominal EAES classification of bile duct injuries during cholecystectomy. *Surg Endosc.* 2013 Dec;27(12):4608-19.



Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. *J Am Coll Surg* 1995;180:101-125.

**Table 9.** Our classification, mechanisms of injury, prevention and treatment

Type	Mechanism of injury	Preventive measures	Treatment for early detection	Treatment for late detection
1	Insecure closure of cystic duct Too deep dissection into gallbladder bed	Attention to operative details	Control bile leak with suturing Laparotomy if required Drain subhepatic space	Drain intraperitoneal collection Control sepsis Endoscopic stenting
2	Incision of CBD instead of cystic duct for operative cholangiogram Clipping of CBD but recognised Laceration of cystic duct/CBD junction Diathermy injury to CBD/CHD	Strasberg's critical view of safety Avoid too much traction on gallbladder Careful use of diathermy	Conversion to laparotomy Repair small laceration Place of T tube controversial Drain subhepatic space If tissue necrosis extensive due to diathermy, treat as Type 3	Early diagnosis without stricture Laparotomy, repair, and drainage Late diagnosis with stricture, treat as Type 3
3	CBD mistaken as cystic duct, with CBD/CHD transected or resected Diathermy injury	Strasberg's critical view of safety Avoid dissection too close to CBD	Conversion to laparotomy Trim divided ducts to healthy tissue Close distal stump HJ to proximal stump Drain subhepatic space	Control sepsis first by draining intraperitoneal collection and proximal bile duct Laparotomy and HJ when sepsis controlled
4	Right HD or sectorial duct mistaken for cystic duct	Recognition of biliary anomaly	Right/left hepatic duct biliary-enteric anastomosis	Asymptomatic: follow up Symptomatic: HJ, liver resection if HJ not possible
5	Right hepatic artery mistaken for cystic artery Diathermy or clip injuries to right hepatic artery during haemostasis	Recognition of vascular anomaly Avoid blind use of diathermy and clip	Reconstruction of vessels and bile ducts if technically possible If not technically possible, ligate duct and vessels and wait and treat as late detection	Asymptomatic with liver atrophy: follow up Symptomatic: HJ±liver resection/liver transplant

CBD: common bile duct; CHD: common hepatic duct; HD: hepatic duct; HJ: hepaticojejunostomy.

*Lau WY, Lai EC. Classification of iatrogenic bile duct injury. Hepatobiliary Pancreat Dis Int 007;6:459-463.*